Complaints Outcomes

Search

Search Results

Search Again
Pharmacist Registrant 34 (Feb 10, 2018)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to suspend his registration as a pharmacist for an indefinite period pending further decision of the Inquiry Committee. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act

Pharmacist Registrant 26 (Jan 17, 2018)

The Inquiry Committee, pursuant to Section 36(1) of the Health Professions Act, has reached an agreement with the pharmacist registrant to amend one of the terms in his Agreement of June 4, 2017. The pharmacist registrant can now work in a pharmacy where narcotic/controlled substances and Z-group drugs are counted and reconciled on a biweekly basis.


June 4, 2017
(January 17, 2018 - Limits and conditions updated)

The Inquiry Committee, pursuant to Section 36(1) of the Health Professions Act, has reached a new revised Agreement with the pharmacist registrant whereby the registrant consented to undertakings that include, but are not limited to:

  1. Complying with all terms of the registrant’s monitoring program for a minimum of three additional years;

  2. Continuing counselling for one year from the date after he had returned to work;

  3. Informing all managers and employers with whom registrant gains employment of registrant’s medical condition and the limits and conditions on registrant’s registration pursuant to the Agreement;

  4. Ensuring that all managers and employers with whom registrant gains employment submits a written statement to the College declaring their awareness of Registrant’s medical condition and the agreement, and how they will accommodate and supervise registrant working in pharmacy;

  5. Working in a pharmacy where narcotic/controlled substances and Z-group drugs are counted and reconciled on a weekly basis;

  6. Working a maximum number of hours and shifts per week for the first three months after signing the Agreement;

  7. Informing his pharmacy manager of all wastages and breakages of narcotic, controlled, opioid and sedative drugs that he has to dispose of or deal with;

  8. Not conducting drug counts and/or conduct medication reconciliation for any narcotic/controlled substances or Z-group drugs;

  9. The registrant will be restricted from acting in the following roles:

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

     

  10. The registrant will notify the College regarding any of the following changes:

    1. changes in places of employment as a pharmacist;
    2. changes in residential address and phone number; and
    3. changes in medical provider;

     

The Agreement will remain in place for a minimum of four years or until such time as the registrant’s physician states otherwise. The name of the registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the registrant. The Inquiry Committee is satisfied that the undertakings will protect the public.


January 3, 2017
(June 4, 2017 – Limits and conditions updated)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended indefinitely on May 16, 2016. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an agreement with the pharmacist registrant whereby the registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. That the registrant will comply with all terms of registrant’s monitoring program with the company currently involved in registrant’s care and remain on this program for a minimum of three (3) years from the day registrant returns to active employment as a pharmacist;

  2. That registrant will continue counselling for one (1) year after registrant returns to work;

  3. That registrant will inform all managers and employers with whom registrant gains employment of registrant’s medical condition and the limits and conditions on registrant’s registration pursuant to this agreement;

  4. That registrant will ensure that all managers and employers with whom registrant gains employment submit a written statement to the College within 48 hours of securing employment, declaring their awareness of registrant’s medical condition and the agreement, how they will accommodate and supervise registrant working in the pharmacy, and that they will submit a weekly narcotic count for a minimum of three (3) months to the College or advise the College if any narcotic count concerns arise;

  5. That after returning to work in a pharmacy setting, registrant will provide work sign-in sheets on a monthly basis;

  6. That registrant will not work alone after returning to work in a pharmacy setting and that there must be overlapping shifts of at least one registrant during registrant’s work shift for a minimum of the first six (6) months that registrant returns to work;

  7. That after returning to work in a pharmacy setting, registrant will not be allowed to dispense narcotics;

  8. That after returning to work in a pharmacy setting, registrant will not handle or physically prepare prescriptions for narcotic, controlled, opioid and sedative drugs, including but not limited to Benzodiazepine, Dextroamphetamine and testosterone products and any Z-Group drugs;

  9. That after returning to work in a pharmacy setting, for the first six (6) months, registrant will not be allowed to dispense Controlled Substances ie. Benzodiazepine, Dextroamphetamine and testosterone products and any Z-Group drugs (which are not considered Controlled Substances);

  10. That after returning to work in a pharmacy setting, registrant will not be allowed to do narcotic or controlled substances or Z-Group drug counts;

  11. That after returning to work in a pharmacy setting, registrant will not dispose or deal with wastage or breakage of or otherwise handle any narcotic, controlled, opioid and sedative drugs, including but not limited to Benzodiazepine, Dextroamphetamine and testosterone products and any Z-Group drugs;

  12. That registrant will not have access to the narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  13. That registrant will not be involved in any way with ordering supplies of narcotic medications;

  14. That registrant will be restricted from acting in the following roles in registrant’s practice: 

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

     

  15. That registrant will be restricted from acting in the following roles in registrant’s practice: 

    1. all changes in places of employment as a pharmacist;
    2. all changes in residential address and phone number; and
    3. all changes in medical provider;

The agreement will remain in place for a minimum of five years from the date of execution of the agreement. The registrant will be assessed by the treating physician after six (6) months upon return to active employment to determine whether or not any of the above limits or conditions should be removed. The name of the registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


May 16, 2016
(January 3, 2017 – Registration Reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant to voluntarily suspend the registration as a pharmacist effective May 16, 2016. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4) of the Health Professions Act.

Pharmacist Registrant 12 (Jan 10, 2018)

Pharmacist Registrant 12 has satisfied all the terms of an agreement reached with the Inquiry Committee dated January 10, 2013.  Limits and conditions on pharmacist registrant’s registration as a pharmacist have now been removed. The registrant’s name has been withheld pursuant to s. 39.3(4) of the Health Professions Act.


July 7, 2015
(January 10, 2018 - Limits and Conditions Removed)

Pharmacist Registrant 12 has satisfied some of the terms of an agreement reached with the Inquiry Committee dated January 10, 2013. At the recommendation of the registrant’s physician, these terms have been removed. The remainder of the terms in the agreement are in effect until January 10, 2018. The registrant’s name has been withheld pursuant to s. 39.3(4) of the Health Professions Act.


January 10, 2013
(July 7, 2015 - Partial limits and conditions removed)

The Inquiry Committee has reinstated pharmacist registrant’s registration that had previously been suspended indefinitely on October 5, 2012. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an agreement with pharmacist registrant to place limits and/or conditions on his registration as a pharmacist effective January 10, 2013. This agreement remains in effect until January 10, 2018. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.


October 5, 2012
(January 10, 2013 – Registration reinstated)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to suspend his registration as a pharmacist for an indefinite period pending further decision of the Inquiry Committee. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act

Lum, King Cheong (Steven) (Jan 1, 2018)

King Cheong (Steven) Lum has completed a term of suspension which ended on December 31, 2017, and is eligible for reinstatement of registration. Until December 31, 2022, he will be limited from being a manager, director or owner of a pharmacy, hold shares in any corporation that owns a pharmacy, and/or be a preceptor.


January 1, 2017
(January 1, 2018 – Registration reinstated)

Pursuant to s. 36(1) of the Health Professions Act, the Inquiry Committee has reached an agreement with King Cheong (Steven) Lum (the “Registrant”) to suspend his registration as a pharmacist for 365 consecutive days, from January 1, 2017 to December 31, 2017.

In or about April 2016, while pharmacy manager, director, and owner of a pharmacy, the Registrant discovered discrepancies between the on-hand quantities and computer quantities of 47 individual molecules of narcotic and controlled drugs and 21 individual molecules of benzodiazepines at the pharmacy. The most significant discrepancies were 165,998 tablets of Ratio-Oxycocet (oxycodone/acetaminophen 5mg/325mg), 1,030 tablets of Ratio-Lenoltec No. 3 (acetaminophen/caffeine/codeine 300mg/15mg/30mg), and 17,353 tablets of Mylan-Alprazolam 2mg. The Registrant had not noticed the discrepancies for many months until April 2016, and therefore the discrepancies had not been reported to Health Canada as required.

After an investigation, it was substantiated that while the Registrant was pharmacy manager, director, and owner of a pharmacy, he failed to maintain a standard of practice of the pharmacy profession and contravened the relevant provincial and federal legislation with respect to the following:

  • Management of inventory of narcotics, controlled drugs and targeted substances under his control to prevent loss or theft, including failure to count and reconcile all narcotics, controlled drugs and targeted substances at least every three months as required by Professional Practice Policy #65;
  • Failure to maintain records of purchases, sales and remaining inventory for narcotics and other controlled drugs;
  • Failure to make timely reports of losses of narcotics and other controlled drugs to Health Canada; and
  • Failure to adhere to s. 43 of the Narcotic Control Regulations, s. G.03.012 of the Food and Drug Regulations, and s. 7(1)(b) of the Benzodiazepines and Other Targeted Substances Regulations, in that he failed to take all reasonable steps that were necessary to protect narcotics, controlled drugs and targeted substances on the premises or under his control against loss or theft or to take steps necessary to ensure their security, including failure to count and reconcile narcotics, controlled drugs and targeted substances at least every three months.

The Inquiry Committee considered that the Registrant’s serious lack of judgment constituted professional misconduct.

Prior to reinstatement of his registration following the suspension period, the Registrant will be required to:

  • thoroughly review relevant legislative requirements and to sign a Declaration acknowledging his understanding of and compliance with the legislative requirements;
  • meet with the Inquiry Committee to discuss his reflections on his conduct and what he has learned;
  • successfully pass the College’s Jurisprudence Exam; and
  • pay a $30,000 fine.

The Registrant will also be limited from being a manager, director, or owner of a pharmacy, hold shares in any corporation that owns a pharmacy, and/or be a preceptor for a period of five years from the date that his suspension ends (commencing December 31, 2017).

The Inquiry Committee considers this Agreement necessary to protect the public, as well as send a clear message to the profession that the College does not tolerate this type of conduct.


May 20, 2016
(January 1, 2017 – Registration suspended)

The Inquiry Committee, pursuant to section 35(1) of the Health Professions Act, R.S.B.C. 1996, c. 183, for the purposes of public protection, has imposed limits and conditions on the practice of registrant King Cheong (Steven) Lum, effective May 20, 2016, pending completion of an investigation of his pharmacy practice. Until further notice, Mr. Lum has the following limits and conditions on his practice:

  1. He will be restricted from the following roles in his practice:

    1. Be an owner or manager of a pharmacy;
    2. Be a director of a corporation that owns a pharmacy; and
    3. Act as a preceptor;

     

  2. He will be restricted from doing the following in relation to narcotic and controlled drugs and substances:

    1. Placing orders; 
    2. Signing wholesaler/manufacturer invoices confirming receipt of orders, or have any sort of signing authority relating to such orders; and
    3. Conducting counts and/or reconciliation of inventory;

     

  3. Prior to the commencement of new employment at any pharmacy, he will inform every manager and employer of the pharmacy in which he gains employment of the limits and conditions on his license pursuant to this order, and will ensure that the pharmacy manager and employer submits a written statement to the College declaring their awareness of the limits and conditions and how the limits and conditions will be accommodated in the pharmacy.

The registrant was the pharmacy manager, director, and owner of a pharmacy, and did not fulfill the responsibilities of a pharmacy manager, director, and owner to operate a pharmacy that met legislative and practice standards. He had not established and/or enforced policies and procedures for inventory management and security and storage of narcotic and controlled drugs, enabling a grossly large quantity of narcotic and controlled medication to be lost and/or taken from the pharmacy and potentially diverted, causing potential harm to the public.

Berra, Patrizia (Dec 18, 2017)

Pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee of the College of Pharmacists of British Columbia (the “College”) reached an agreement by consent with pharmacist registrant Patrizia Berra (the “Registrant”) to suspend her registration as a pharmacist for a period of one month from January 22, 2018 to February 21, 2018.

A member of the public obtained a printout of her PharmaNet record and discovered that the Registrant accessed her PharmaNet record. The Registrant admitted that she did not dispense a medication, provide patient counselling or evaluate a patient’s drug usage when she accessed the patient’s PharmaNet record, and that the access was without consent.

Following investigation, the Inquiry Committee determined that the Registrant inappropriately accessed a PharmaNet record for reasons unrelated to health care and without consent, in contravention of sections 21(2) and 21(3) of the Bylaws to the Pharmacy Operations and Drug Scheduling Act, section 71 of the Bylaws to the Health Professions Act, and Standard 4 of the Code of Ethics.

The Inquiry Committee found that this constitutes a “serious matter” and that inappropriate access of personal health information compromises the public’s trust in individual registrants and the pharmacy profession as a whole. Previous complaints considered by the Inquiry Committee have found that even inadvertent and innocuous inappropriate access by a registrant is sufficient for an onerous disposition.

Therefore, the Inquiry Committee and the Registrant agree that the Registrant shall submit a fine of $1,000, suspend her registration for a period of one month, and thereafter appear before a panel of the Inquiry Committee for a verbal reprimand. A letter of reprimand shall be placed on the College register as a permanent record and the College may disclose its contents in response to inquiries regarding the status of the Registrant’s registration. The Inquiry Committee considers this agreement necessary to protect the public.

Lam, Alexis Vanessa (Dec 8, 2017)

Alexis Vanessa Lam has satisfied all the terms of an agreement reached with the Inquiry Committee dated May 9, 2017.  Limits and conditions on pharmacist registrant’s registration as a pharmacist have now been removed. 


May 9, 2017
(December 8, 2017 - Limits and conditions removed)

The Inquiry Committee, pursuant to section 35(1)(a) of the Health Professions Act, R.S.B.C. 1996, c. 183, for the purposes of public protection, has imposed limits and conditions on the practice of registrant Alexis Vanessa Lam, pending completion of an investigation of her pharmacy practice. Until further notice, Ms. Lam has the following limits and conditions on her practice:

  1. Effective May 9, 2017, she will be restricted from doing the following in relation to narcotic and controlled drugs and substances:
    1. Placing and receiving orders; and
    2. Signing wholesaler/manufacturer invoices confirming receipt of orders, or have any sort of signing authority relating to such orders.

Ms. Lam has not demonstrated that she has fulfilled her responsibility as a registrant to take reasonable steps to protect narcotic and controlled drugs against loss in or from the pharmacy where she works. In addition, she has not kept accurate records regarding all purchases and sales of narcotic and controlled drugs. This has enabled a large quantity of narcotic and controlled drugs at the pharmacy to be unaccounted for, causing potential harm to the public.

Pharmacist Registrant 4 (Nov 23, 2017)

 

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant to voluntarily suspend the registration as a pharmacist effective November 23, 2017. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4) of the Health Professions Act.


February 20, 2015
(November 23, 2017 - Registration Suspended)

Pharmacist Registrant 4 has satisfied the terms of an agreement reached with the Inquiry Committee dated April 1, 2010. Limits and conditions on pharmacist registrant’s registration as a pharmacist have now been removed. The pharmacist registrant’s name has been withheld pursuant to 39.3(4) of the Health Professions Act.


April 1, 2010
(February 20, 2015 - Limits and conditions removed)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to place limits and/or conditions on his registration as a pharmacist effective April 1, 2010. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.

Robertson, Chadwick Aaron (Nov 22, 2017)

On a series of occasions during 2015, Chadwick Aaron Robertson (the “Registrant”) made comments to LC, an individual posing as an athlete, about the use of banned drugs and their suitability for the purpose. The Registrant provided LC a training protocol that was never put into operation. Unbeknownst to the Registrant, LC was part of an “undercover” investigation and the Registrant’s meetings and other dealings with LC were being videotaped. An edited version of the footage was ultimately broadcast over the Internet.  The College considers, and the Registrant concedes, that this conduct reflected negatively on the Registrant and the profession of pharmacy in British Columbia. It constitutes professional misconduct, a serious matter pursuant to section 26 of the Health Professions Act

For the above conduct, pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee has reached a consent agreement with the Registrant for the following terms and undertakings:

  • That the Registrant’s registration as a Full Pharmacist be suspended for a period of six (6) months, to commence on November 22, 2017;
  • That the Registrant pay a $10,000.00 fine to the College no later than November 22, 2018;
  • That a letter of reprimand be placed permanently on the College’s register;
  • That he appear before a panel of the Inquiry Committee for a verbal reprimand;
  • That he successfully complete the ProBE Program on Professional/Problem-Based Ethics for healthcare professionals no later than November 22, 2018; and
  • That he thoroughly review relevant legislation and complete the College’s Code of Ethics Educational Tutorial and sign declarations acknowledging his understanding and compliance with legislative and ethical requirements.
Pharmacist Registrant 33 (Sep 11, 2017)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant to not engage in the practice of pharmacy. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4) of the Health Professions Act.

Pharmacist Registrant 31 (Aug 22, 2017)

The Inquiry Committee has reinstated Pharmacist Registrant’s registration which had previously been suspended for an indefinite period on March 20, 2017. Pursuant to Section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings. The undertakings include, but are not limited to: 

  1. The Registrant will adhere to his routine medical monitoring program with the institution currently involved in his case and remain on the monitoring program for three years;

  2. The Registrant will not work alone in a pharmacy, and will, at all times, have another pharmacist or pharmacy technician/assistant/staff on site at all times;

  3. The Registrant will not have any access whatsoever, on or off-duty, to the narcotic safe in any pharmacy;

  4. The Registrant will not be involved in any way with ordering narcotic medications, except for signing off on the necessary paperwork in the presence of a witnessing pharmacy staff member for the purposes of receiving and stocking such narcotics;

  5. The Registrant will not dispense his own medications;

  6. The Registrant shall disclose to the pharmacy manager/or employer the limits and conditions on his license pursuant to the agreement prior to the commencement of new employment at any pharmacy;

  7. The Registrant will ensure that the pharmacy manager and/or employer with whom the Registrant secures employment submits a written statement to the College declaring their awareness of the Registrant’s medical condition and the agreement;

  8. The Registrant will notify the College, in writing or via e-mail, of his places of employment as a pharmacist and report any changes to the location of his employment within 48 hours of such change. A reportable change to the Registrant’s place of employment contemplates both commencement and termination of employment;

  9. The Registrant will be restricted from acting in the following roles in his practice

    • Be a manager of a pharmacy;
    • Be a director of a corporation that owns a pharmacy; and
    • Act as a preceptor.

     

The Agreement will remain in place until such time as the Registrant’s physician states otherwise. The name of the registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the registrant. The Inquiry Committee is satisfied that the undertakings will protect the public.


March 20, 2017
(AugUst 22, 2017 – Registration reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an agreement by consent with the pharmacist registrant to voluntarily suspend registration as a pharmacist effective March 20, 2017. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4) of the Health Professions Act.

Pages